Why BridgeBio Pharma (BBIO) Stock Is Down Today

BridgeBio Pharma (BBIO) is down 5.7% today. Here is some analysis on what might have caused this price movement.

Analysis: A clear new negative catalyst was not obvious, so the sell-off appears tied to profit-taking after a recent run of upbeat pipeline updates and management conference appearances. This could also be because investors were looking for fresh upside commentary at today’s healthcare conference and instead got a more familiar update, while the stock still faces some share-supply overhang from August’s secondary offering.

Details:

BridgeBio scheduled a management presentation for the Morgan Stanley healthcare conference on Tuesday, September 15, 2026, which can create volatility when investors do not hear materially new information.

Management’s September conference commentary highlighted upcoming launches, ongoing commercialization of Attruby, and multiple late-stage programs, but the broad message largely reinforced prior guidance rather than introducing a major new catalyst.

The company released new achondroplasia data on September 9 showing favorable trends for oral infigratinib beyond growth measures, so some of today’s weakness may reflect traders locking in gains after that recent positive news flow.

BridgeBio also completed a 5 million-share secondary offering in August on behalf of an existing shareholder, which did not raise cash for the company but may still be contributing to trading pressure and supply concerns.

Sources:

BridgeBio Pharma, SEC, Stock Analysis

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$BBIO Insider Trading Activity

$BBIO insiders have traded $BBIO stock on the open market 49 times in the past 6 months. Of those trades, 0 have been purchases and 49 have been sales.

Here’s a breakdown of recent trading of $BBIO stock by insiders over the last 6 months:

JENNIFER E. COOK has made 0 purchases and 6 sales selling 278,192 shares for an estimated $21,920,434.
NEIL KUMAR (Chief Executive Officer) has made 0 purchases and 34 sales selling 231,083 shares for an estimated $16,921,841.
ANDREA ELLIS sold 17,167 shares for an estimated $1,442,028
RANDAL W. SCOTT has made 0 purchases and 4 sales selling 10,000 shares for an estimated $671,455.
HANNAH VALANTINE has made 0 purchases and 2 sales selling 5,004 shares for an estimated $341,523.
MARICEL APULI (Chief Accounting Officer) has made 0 purchases and 2 sales selling 4,000 shares for an estimated $303,280.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

$BBIO Hedge Fund Activity

We have seen 258 institutional investors add shares of $BBIO stock to their portfolio, and 258 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

BLACKROCK, INC. removed 3,920,601 shares (-27.6%) from their portfolio in Q2 2026, for an estimated $292,006,362
WELLINGTON MANAGEMENT GROUP LLP added 2,824,971 shares (+113.7%) to their portfolio in Q2 2026, for an estimated $210,403,840
BROOKLANDS FUND MANAGEMENT LTD removed 2,750,000 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $204,215,000
CITADEL ADVISORS LLC added 2,475,758 shares (+354.6%) to their portfolio in Q1 2026, for an estimated $183,849,789
JPMORGAN CHASE & CO added 2,397,995 shares (+inf%) to their portfolio in Q2 2026, for an estimated $178,602,667
PRICE T ROWE ASSOCIATES INC /MD/ removed 2,075,272 shares (-54.6%) from their portfolio in Q2 2026, for an estimated $154,566,258
FRAZIER LIFE SCIENCES MANAGEMENT, L.P. removed 1,900,000 shares (-55.1%) from their portfolio in Q2 2026, for an estimated $141,512,000

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$BBIO Congressional Stock Trading

Members of Congress have traded $BBIO stock 4 times in the past 6 months. Of those trades, 4 have been purchases and 0 have been sales.

Here’s a breakdown of recent trading of $BBIO stock by members of Congress over the last 6 months:

REPRESENTATIVE GILBERT RAY CISNEROS, JR. has traded it 4 times. They made 4 purchases worth up to $60,000 on 05/11, 04/29, 03/19, 03/18 and 0 sales.

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.

$BBIO Price Targets

Multiple analysts have issued price targets for $BBIO recently. We have seen 8 analysts offer price targets for $BBIO in the last 6 months, with a median target of $101.0.

Here are some recent targets:

Salim Syed from Mizuho set a target price of $96.0 on 06/16/2026
Whitney Ijem from Canaccord Genuity set a target price of $104.0 on 06/03/2026
Raghuram Selvaraju from HC Wainwright & Co. set a target price of $110.0 on 05/28/2026
Sean Laaman from Morgan Stanley set a target price of $98.0 on 05/28/2026
Eric Joseph from Citigroup set a target price of $82.0 on 05/19/2026
Cory Kasimov from Evercore ISI Group set a target price of $130.0 on 05/08/2026
Danielle Brill from Truist Securities set a target price of $102.0 on 04/29/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.